Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child‐specific reference values-Reference-Cited by-同舟云学术

Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child‐specific reference values

Published:2019-03-21 Issue:6 Volume:66 Page:e27671
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Løvvik Juul‐Dam Kristian¹^ORCID,Guldborg Nyvold Charlotte²³,Vålerhaugen Helen⁴,Zeller Bernward⁵,Lausen Birgitte⁶,Hasle Henrik¹,Beier Ommen Hans²

Affiliation:

1. Department of Pediatrics and Adolescent MedicineAarhus University Hospital Aarhus Denmark

2. Department of HematologyAarhus University Hospital Aarhus Denmark

3. Hematology‐Pathology Research LaboratoryDepartment of HematologyOdense University Hospital Odense Denmark

4. Department of PathologyThe Norwegian Radium Hospital Oslo Norway

5. Division of Pediatric and Adolescent MedicineOslo University Hospital Oslo Norway

6. Department of Pediatrics and Adolescent MedicineRigshospitalet, University of Copenhagen Copenhagen Denmark

Funder

Børnecancerfonden

Karen Elise Jensens Fond

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27671

Reference32 articles.

1. Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate

2. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

3. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

4. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

5. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia;Frontiers in Oncology;2024-04-24

2. Measurable Residual Disease Assessment in Pediatric AML;Pediatric Oncology;2024

3. Combined expression of WT1/PRAME genes and BIRC5/PRAME genes and their clinical significance in adult patients with acute myeloid leukemia;The Egyptian Journal of Haematology;2023-04

4. Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance;2022-04-02

5. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia;The Journal of Molecular Diagnostics;2021-12